Loracarbef Anhydrous

Summary

Loracarbef Anhydrous (CHEMBL1013) is an approved small molecule.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Chemistry: 349.77 Da · C16H16ClN3O4

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1013
Name	Loracarbef Anhydrous
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	5284585
ChEBI	CHEBI:214480
Molecular formula	C16H16ClN3O4
Molecular weight	349.77
InChIKey	JAPHQRWPEGVNBT-UTUOFQBUSA-N

SMILES: C1CC(=C(N2[C@H]1[C@@H](C2=O)NC(=O)[C@@H](C3=CC=CC=C3)N)C(=O)O)Cl

IUPAC name: (6R,7S)-7-[[(2R)-2-amino-2-phenylacetyl]amino]-3-chloro-8-oxo-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid

ChEBI definition: The zwitterionic form of loracarbef.

Also known as: Anhydrous loracarbef, Loracarbef anhydrous, Loracarbef, anhydrous, Lorbef, LY-163892, lcbf, LORACARBEF, loracarbef, LORACARBEF ANHYDROUS

Parent form; salt/anhydrous children: CHEMBL1200610

Patent coverage: 4,263 distinct patent families (17,086 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).